Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | TDO2 | P48775 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.33 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29629244 | 0.82 | ALOX5 (0.41) | AOC3 | |
| SCHEMBL11960067 | 0.80 | STAT3 (0.42) | — | |
| SCHEMBL11960068 | 0.78 | TSHR (0.46) | AOC3HDAC4HDAC7HDAC5 | |
| SCHEMBL4641824 | 0.77 | TRPA1 (0.44) | TRPA1 | |
| SCHEMBL31190067 | 0.75 | PTGS2 (0.50) | — | |
| SCHEMBL8773918 | 0.74 | MEN1 (0.52) | AOC3IDO1TDO2HDAC3HDAC4 | |
| SCHEMBL10077145 | 0.74 | AOC3 (0.37) | AOC3IDO1TDO2HDAC3HDAC4 | |
| SCHEMBL1712779 | 0.73 | HDAC3 (0.42) | AOC3IDO1TDO2HDAC3HDAC4 | |
| SCHEMBL3885072 | 0.73 | ORAI1 (0.42) | AOC3IDO1TDO2HDAC3HDAC4 | |
| SCHEMBL15833075 | 0.73 | HDAC3 (0.42) | AOC3IDO1TDO2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-14 | — | — | US | disclosed |
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-14 | — | — | US | disclosed |
| US-9771592-B2 | Methods and compositions for treating or preventing pruritis | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771592-B2 | Methods and compositions for treating or preventing pruritis | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20140303231-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-10-09 | — | — | US | disclosed |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | AOC3 273/4885IDO1 807/4885TDO2 3880/4885 |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MRGPRX1, MRGPRX2, MRGPRX4 | AOC3 1379/4885IDO1 985/4885TDO2 1449/4885 |
| US-20140303231-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | AOC3 273/4885IDO1 807/4885TDO2 3880/4885 |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | AOC3 273/4885IDO1 807/4885TDO2 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.